跳到正文

临床研究评估与证据追溯

为汇总层面的临床研究整理证据、评价、模型和治理材料,提供 GRADE 资料与逻辑追溯检查;适用研究用途。

开源精选医疗业务31 个文件50,135 Stars浏览次数 0K-Dense-AI/scientific-agent-skills MIT版本 a1043ef
开始使用

适用环境:Python 3.11+; local files only; bundled scripts use the standard library and require no network, credentials, API keys, LLMs, or image services.

输入资料
汇总或原文允许的研究材料 预先明确的研究问题与评价目标 阅读本节完整说明
交付内容
研究评价与证据资料 来源、限制与人工复核清单 阅读本节完整说明
  1. 获取完整包,保留配套文件的目录结构。
  2. 按照原文准备所需工具、依赖与输入资料。
  3. 阅读对应使用步骤与输入输出说明,在自己的环境中验证结果。

使用提示摘自原文,配套文件保留来源版本;实际运行条件以各包说明为准。

正文

获取原文件

references/model_biomarker_evaluation.md

Boundary

Evaluate a locked model, assay, or prespecified biomarker rule using synthetic or aggregate validation summaries. Do not:

  • ingest individual records;
  • discover or optimize a threshold;
  • assign a class or risk to a person;
  • match a person to a test or intervention;
  • state clinical validity, utility, safety, or fitness for deployment.

Define the Target

Record:

  • evaluation target and version;
  • biomarker category using FDA-NIH BEST terminology;
  • intended research purpose;
  • target population, setting, prevalence, and outcome horizon;
  • intended user and non-clinical decision role;
  • inputs, output, threshold, and threshold provenance;
  • development, tuning, internal-test, and external-validation datasets;
  • whether evaluation is temporal, geographic, site-based, or population-based.

Do not call a random split from one source “external validation.”

Analytical and Clinical Questions

Keep separate:

  1. Analytical validation — measurement accuracy, precision, detection limits, reproducibility, interference, specimen stability.
  2. Clinical validation — association or predictive performance for the defined context.
  3. Clinical utility — whether use improves meaningful outcomes compared with alternatives.

The bundled evaluator addresses only selected aggregate clinical-validation performance summaries. It cannot establish any of the three.

Performance Dimensions

Discrimination

Depending on the target:

  • sensitivity and specificity;
  • predictive values, with prevalence/context;
  • likelihood ratios;
  • C statistic/AUC with uncertainty;
  • time-dependent discrimination for censored outcomes.

Do not report accuracy alone when classes are imbalanced.

Calibration

Calibration asks whether predicted probabilities agree with observed frequencies. Evaluate:

  • calibration-in-the-large;
  • calibration slope;
  • calibration plots with uncertainty;
  • observed versus predicted risk across meaningful ranges;
  • integrated or absolute calibration error when justified.

The standard-library helper accepts calibration bins and reports a weighted absolute gap. Its calibration_in_the_large_gap field is mean predicted probability minus observed event proportion on the probability scale; it is not the logistic calibration intercept. Bin totals and observed events must match the same group and confusion matrix, including when disclosure suppression applies. Binning loses information and does not replace individual-level calibration analysis in an approved environment.

Primary overview: Van Calster et al., calibration.

Overall Accuracy and Utility

Use proper scoring rules and decision-curve/net-benefit methods only with a prespecified, defensible decision context. Do not imply utility from AUC or accuracy. Utility evaluation that changes care is outside this skill.

Uncertainty

Report intervals for performance estimates and explain resampling or analytic methods. A zero denominator is undefined, not zero performance: the helper emits null estimates/interval endpoints. Balanced accuracy requires both observed outcome classes, otherwise it is null and excluded from subgroup differences. The helper uses Wilson intervals for aggregate proportions. It does not model correlated observations, clustering, repeated measurements, censoring, or verification bias.

External Validation

Apply the original locked model without refitting. Document:

  • differences in case mix, prevalence, setting, workflow, and measurement;
  • eligibility and missingness;
  • sample-size rationale based on precision targets, not a blanket event rule;
  • calibration, discrimination, and any prespecified utility measure;
  • subgroup performance;
  • model failures and unusable inputs;
  • whether recalibration was separate from validation.

See BMJ 2024 external-validation guidance and sample-size methodology.

Subgroup and Fairness Evaluation

Before analysis:

  • identify groups based on intended use, evidence, and stakeholder input;
  • document category provenance and limitations;
  • set minimum precision and disclosure rules;
  • plan intersectional analyses where feasible;
  • define metrics and acceptable uncertainty;
  • evaluate measurement and label validity;
  • plan investigation and mitigation, not only detection.

Report:

  • representation and missingness;
  • performance and calibration with intervals;
  • data quality and failure rates;
  • distribution shift;
  • human-AI interaction where relevant;
  • observed differences without declaring a group deficient.

No single parity metric establishes fairness. Equal metrics can coexist with inequitable outcomes, and unequal metrics may reflect case mix, measurement, structural conditions, or model behavior that requires investigation.

Biomarker-Specific Controls

  • Pre-specify specimen, assay, platform, software, quality controls, units, and threshold.
  • Preserve continuous information where appropriate.
  • Separate prognostic association from treatment-effect interaction.
  • Blind assay assessment to outcome when feasible.
  • Account for batch/site effects and failed measurements.
  • Validate thresholds independently.
  • Report analytical validity before clinical interpretation.
  • Use REMARK for tumor prognostic markers.

Change Control and Monitoring

For each release record:

  • immutable model/assay version;
  • data and code versions;
  • planned changes and rationale;
  • validation protocol and acceptance criteria;
  • subgroup/calibration regression tests;
  • human-factors impact;
  • approval and rollback;
  • monitoring cadence and drift triggers;
  • incident handling and retirement.

Never update a threshold or model silently after viewing performance.

Aggregate Evaluator

Input contains only:

  • group labels and aggregate denominators;
  • confusion counts;
  • aggregate calibration bins;
  • provenance and validation metadata.

Output contains bounded descriptive metrics, uncertainty, suppression, and documented gaps. Invalid inputs return failure diagnostics with no partial group metrics. The helper emits JSON only; it does not produce calibration plots, bin-level Wilson intervals, forest plots, or fitted calibration models. It never outputs a person-level class or recommendation.

python3 scripts/model_biomarker_evaluation.py \
  assets/aggregate_model_evaluation_template.json

CONTACT HAONAN

联系haonan

医疗 AI · 产品与独立开发

刘浩南

关注医疗 AI 从 demo 到真实落地,聚焦产品化、商业化与院内工作流效率提升。

12年医疗产研经验,大湾区头部医疗AI公司前产品总监,独立开发者

医疗 AI 产品化医疗 AI 商业化院内工作流效率
刘浩南的微信联系二维码
微信扫一扫,联系 haonan